This is Sobi

Investor presentation

July 2025

Forward-looking statements

This presentation contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Table of contents	Slide

Sobi: Global biopharma company developing and commercialising rare disease therapies

Clear strategy with proven execution:

- **Identify**: Successful BD track record building pipeline via partnerships and acquisitions
- **Unlock**: Deep clinical-stage pipeline spanning multiple rare disease areas
- **Level Up**: 13 primary medicines on market

2024 accomplishments set the stage to drive future growth

Multiple global catalysts expected in 2025

SEK 26,027 M 2024 revenue, +19% growth at CER

Head office in Stockholm with hubs in Basel, Switzerland and Waltham, MA (US), ~1,900 employees

Rare diseases are an attractive market and expected to grow faster than general pharma

- **~10,000 rare disease** have been identified with only an estimated 130 with marketed treatments
- **High medical unmet need** and treatments offering significant benefit
- **Governance and regulatory incentives** including faster path to approval and greater regulatory protection with orphan designation

Rare disease overall market expected to grow 9% until 2028[1]

Orphan (ex. solid tumors Oncology) (USD bn)



Total pharma market expected to grow 7.5% between 2022-2028

Sobi well positioned within rare diseases

Current Sobi areas

Therapeutic category	Worldwide annual sales estimates , USD Bn[2]		
	2023	2028	CAGR, %
Oncology	68.3	112.8	11
Haematology	22.8	34.4	9
CNS	13.5	28.4	16
Immunology	6.1	17.7	24
Musculoskeletal	7.0	17.3	20
Respiratory	15.1	14.6	-1
Various	8.3	13.5	10
Cardiovascular	5.7	11.9	16
Endocrine	4.4	5.7	5
Systemic anti-infectives	1.6	4.7	24
Sensory organs	2.1	3.7	12
Gastro-intestinal	1.4	3.5	20

1: Evaluate Pharma Market Analyzer 2024 filtered for Orphan Drugs and excluding Solid Tumors Rare disease pharma:
2: Evaluate Pharma Orphan Drug report 2024

Business model - source, develop and commercialise in the rare disease space

Identify

- Acquisitions
- Licensing



Unlock

Driving clinical development with potential new molecules and expansion of existing medicines

Asset	Indication	Phase 2	Phase 3	Registration
Aspaveli/Empaveli (pegcetacoplan)	C3G and IC-MPGN			
	Post-HSCT-associated microangiography			
Gamifant (emapalumab)	sHLH / MAS in rheumatological diseases			
Zynlonta (loncastuximab tesirine)	Diffuse large B-cell lymphoma, second line			
NASP (formerly SEL-212)	Chronic refractory gout			
Vonjo (pacritinib)	Myelofibrosis with severe thrombocytopenia			
	VEXAS			
Doptelet (avatrombopag)	ITP, Japan and pediatric ITP (US)			

Level Up

2024: Revenue: SEK 26,027 M (+19% at CER)

Europe +14%
North America + 4%
International +14%
Other (including Beyfortus and Altuviiio royalty) +85%

pHLH: Primary hemophagocytic lymphohistiocytosis, sHLS: secondary hemophagocytic lymphohistiocytosis, MAS: Macrophage activation syndrome, ITP: Immune thrombocytopenic purpura, PNH: Paroxysmal nocturnal hemoglobinuria, MF: Myelofibrosis

Strong record of successful achievements in delivering medicines to rare disease patients around the world

Selected examples from the Sobi portfolio

	gamifant® emapalumab-lzsg	Doptelet® (avatrombopag) tablets	ASPAVELI® (pegcetacoplan)	VONJO® (pacritinib) capsules
Identify	Novimmune	Dova	Apellis	CTI Pharma
Unlock	pHLH - FDA approval 2018 HLH/MAS filed in US under fast-track designation in December 2024	ITP - FDA approval 2018 EU approval 2021 International expansion ongoing Paediatric indication filed in US in 2024	PNH - EU approval 2021 International expansion ongoing Nephrology indications filed in EU in January 2025	MF – FDA approval 2022 CTI integrated, launch ongoing Future development options initiated
Level Up	SEK 1,876 M +14%	SEK 3,870 M +30%	SEK 1,030 M +76%	SEK 1,462 M >108%

Revenue 2024, % growth, year over year at CER

pHLH: Primary hemophagocytic lymphohistiocytosis, sHLS: secondary hemophagocytic lymphohistiocytosis, MAS: Macrophage activation syndrome, ITP: Immune thrombocytopenic purpura, PNH: Paroxysmal nocturnal hemoglobinuria, MF: Myelofibrosis

Identify

Next wave of catalysts to drive growth

Asset	Indication	Phase 2	Phase 3	Registration	
Aspaveli/Empaveli (pegcetacoplan)	C3G and IC-MPGN				Pivotal VALIANT data presented at ASN Kidney Week 2024; Filed in EU February 2025
	Post-HSCT-associated microangiography				
Gamifant (emapalumab)	HLH / MAS in Stills disease				FDA priority review – PDUFA June 2025
	Interferon driven Sepsis				EMBRACE Phase 2a study recruiting
Zynlonta (loncastuximab tesirine)	Diffuse large B-cell lymphoma, second line				LOTUS-5 study fully recruited
NASP (formerly SEL-212)	Uncontrolled gout				FDA Fast Track Designation granted 2024; Rolling Biologics License Application (BLA) initiated July 2024
Vonjo (pacritinib)	Myelofibrosis with severe thrombocytopenia				PACIFICA confirmatory study ongoing
	VEXAS				Phase 2 PRAXIS study initiated
Doptelet (avatrombopag)	ITP, Japan Pediatric ITP, US				Japan –ITP indication submitted 2024 US- ITP Pediatric indication submitted 2024

C3G, Complement 3 glomerulopathy; IC-MPGN, Immune complex membranoproliferative glomerulonephritis; HSCT, Hematopoietic Stem Cell Transplantation; sHLH, Secondary hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; ITP, Immune thrombocytopenia

Unlock

Strong progress in pipeline in 2024

Altuvoct	Haemophilia-A: EU approval		
Aspaveli/ Empaveli	C3G and IC-MPGN: Positive VALIANT Phase 3 data	C3G and IC-MPGN: Submission to EMA*	PNH: First-line approval in EU
Vonjo	VEXAS: IND granted by FDA		
Doptelet	ITP: Paediatric extension submitted to FDA	ITP: submitted in Japan	ITP: approval in China
Gamifant	HLH/MAS in Still's disease: sNDA submitted to FDA		
NASP (SEL-212)	CRG: Rolling US submission initiated		
Kineret	Still's: approval in China	Still's: completion of Japanese study	

*Submitted in February 2025

C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. CRG: Chronic refractory gout.

HLH/MAS: Haemophagocytic lymphohistiocytosis / macrophage activation syndrome. ITP: immune thrombocytopenia. VEXAS: Vacuoles E1 Ub activating enzyme X-linked Auto-inflammatory disease with Somatic mutations.

Growth driven by core business area and all regions

Sales (SEK B)



Sales (SEK B)



Looking ahead to 2025

Anticipated major pipeline news flow

2025

Aspaveli / Empaveli – Nephrology	• EU regulatory decision • Japan regulatory submission	
Gamifant[1] – HLH / MAS 	• US regulatory decision • Japan regulatory submission	
Altuvoct – Haemophilia A	• FREEDOM (Phase 3b) interim data	
NASP – Uncontrolled gout 	• US finalisation of rolling submission	
Kineret – Still's disease	• Japan regulatory submission	

1. EU submission strategy to be announced in 2025
C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
sHLH / MAS: secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome in patients with underlying rheumatological diseases, specifically Still´s disease and systemic lupus erythematosus; DLBCL: Diffuse large B-cell lymphoma.



2025 outlook

Revenue

Anticipated to grow by a high-single digit percentage at CER

Adjusted EBITA margin

Anticipated to be in the mid-30s percentage of revenue

Sobi’s near term building block of the future

Investment in 2025 for multiple launches in 2025/26

2

Major launches

1. Altuvoct
2. Vonjo

3

Key filing

1. Gamifant - HLH/MAS
2. Aspaveli - C3G/IC-MPGN
3. NASP - uncontrolled gout

4

Priority development projects in area of high unmet medical need

1. Gamifant - IDS
2. Vonjo - VEXAS
3. Vonjo - CMML
4. Altuvoct - synovitis

NASP: nanoencapsulated sirolimus plus pegadricase, CMML: Chronic myelomonocytic leukaemia, IDS: Interferon-gamma driven sepsis

Reason to Invest

Sobi: Unlocking the potential of breakthrough therapies, transforming everyday life for people living with rare diseases

Solid foundations

- Track record of identification of assets at late stage (relatively derisked)
    - Strong partner in the rare disease space
- Globally diversified business with strong EU and US business with continuous international growth
- Solid foundation in rare Haematology and Immunology
- Experienced leadership team
- Strong financial performance

Bright future

- Growing on market portfolio with active launches
    - Altuvoct (EU)
    - Vonjo (US)
- Multiple options unlocking future growth near term with 3 new potential launches in 2025/2026
    - Aspaveli in Nephrology (EU)
    - NASP in uncontrolled gout (US)
    - Gamifant in HLH/MAS (US)
- Longer-term in-house development options (Gamaifant, Vonjo & Altuvoct) supported by continuous strong business development

Management Team

Guido Oelkers
Chief Executive Officer

Henrik Stenqvist
Chief Financial Officer

Lydia Abad-Franch
Chief Medical Officer, Head of R&D and Medical Affairs

Duane H. Barnes
Head of North America

Lena Bjurner
Head of Human Resources

Sofiane Fahmy
Head of Europe

Torbjörn Hallberg
General Counsel & Head of Legal Affairs

Mahmood Ladha
Head of Strategic transformation operations

Norbert Oppitz
Head of International

Daniel Rankin
Head of Strategy & Corporate Development

Christine Wesström
Head of Technical Operations

sobi.com/executive committee

Latest results
Q2 2025 and business area update

Q2 Highlights: Growth, Portfolio Expansion & Pipeline Milestones

Continued Portfolio growth, +22% at CER

Revenue Q2: SEK 6,175 M, +22%

Adjusted EBITA margin Q2: 34%

Strategic portfolio[1] accounts for 55% of revenue in the quarter - growing 65% at CER

- Altuvoct® SEK 627 M
- Doptelet® SEK 1,220 M, +43%
- Aspaveli®/Empaveli® SEK 304 M, +28%
- Gamifant® SEK 632 M, +33%
- Vonjo® SEK 302 M, -4%
- Altuviiio® royalties SEK 248 M, +98%

Key milestones achieved on track for late-stage pipeline

- Gamifant: approved by FDA for HLH/MAS in Still's disease
- NASP: completed filing with FDA for uncontrolled gout, pending acceptance of file

2025 outlook - unchanged

Revenue: anticipated to grow by a high-single digit percentage at CER
Adjusted EBITA margin: anticipated to be in the mid-30s percentage of revenue

Per cent growth calculated in CER

1: Strategic portfolio includes Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta and royalties from Altuviiio and Beyfortus.

Delivering strong Q2 growth & advancing long-term value

Underpinned by robust portfolio performance and global delivery

Revenue by segment

	Q2 2025 SEK M	change %	contrib. %
Haematology	4,570	+27	74
– Haemophilia	*2,699*	*+24*	*43*
Immunology	1,288	+11	21
Specialty care	317	+13	5
Total	**6,175**	**+22**	**100**

Revenue by region

	Q2 2025 SEK M	change %
Europe	2,626	+21
North America	2,126	+16
International	900	+44
Other (Royalty)	523	+22

Revenue at actual exchange rates; change at constant exchange rates (by segment and geographic area). International region previously called rest of the world.
Other refers to royalty and the majority of royalties received are attributable to North America

Strong momentum across the portfolio in Q2



- Haemophilia A sales: Growing 32% driven by robust Altuvoct launch
- Doptelet: Continued strong demand across markets with 43% growth
- Aspaveli/Empaveli: Continued growth in number of patients across markets even with competitive pressure growing in PNH
- Vonjo: -4% decrease in the quarter, continued demand outweighed by impact from gross to net adjustments
- Kineret: 10% growth supported by increased demand across regions
- Gamifant: Strong performance in demand in Q2 with 33% growth

Growth at CER

Altuvoct: Launches continue in Europe and Middle East

Haemophilia A sales (Altuvoct +Elocta) grew 32% in Q2

Haemophilia A sales
SEK 1,618 M
+32% Q2



Altuvoct launch:

- **Second quarter 2025 sales of SEK 627 M**
  - Strong launch progress with initial sales in 17 countries led by Germany, Switzerland, and Spain. UK full launch in July
  - Continued switching from Elocta and competing therapies, including non-factor products
  - Effective once-weekly treatment for enhanced bleed protection & treatment burden as a key clinical benefit in normalisation for FVIII levels*

ALTUVOCT®
efanesoctocog alfa (recombinant coagulation factor VIII, Fc-Von Willebrand Factor-XTEN Fusion Protein)

*above 40% for a significant part of the week (4 days for adults and 3 days for children and adolescents)
Sales in SEK M at actual exchange rates; change at constant exchange rates

Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026

Aspaveli/Empaveli
SEK 304 M
+28% Q2



PNH

- Continued growth across markets with strong YoY growth, competitive pressure in PNH growing in Europe

Nephrology*

- EU: CHMP opinion expected by end 2025
- Best in class profile: 52-week VALIANT data presented at ERA 2025

Royalty agreement update

- Reduction in ex-U.S. royalty obligation to Apellis Pharmaceuticals, Inc. by 90% until defined caps are achieved, after which ex-U.S. royalties revert to the original license agreement
- Upfront payment: $275 million in cash
- Up to $25 million upon EMA approval of Aspaveli for C3G and primary IC-MPGN

ASPAVELI® (pegcetacoplan)

VALIANT: Phase 3 study of pegcetacoplan in C3G and primary IC-MPGN

*US FDA submission by Apellis Pharmaceuticals; ex-US submission by Sobi.
Sales in SEK M at actual exchange rates; change at constant exchange rates.

Vonjo: Demand growing but sales impact from gross to net adjustments

Vonjo
SEK 302 M
-4% Q2



- Demand increasing vs PY in Q2: +11% volume growth
- Net sales -4% in Q2
- GTN impact due to recent changes in reimbursement

Strategic progress: (Focus**:** label expansion, guideline support, Internationalization and new indications)

- PACIFICA Phase 3 confirmatory study in MF: recruitment acceleration due to activation of international sites
- PAXIS study in VEXAS: enrolment in line with expectations, and high interest in the scientific community
- Continued dialogue with relevant stakeholders to facilitate label expansion and support guidelines* update

VONJO (pacritinib) capsules

Sales in SEK M at actual exchange rates; change at constant exchange rates

*In addition to being the preferred option in its indicated population of intermediate and high-risk MF patients with a platelet count <50K, the updated NCCN guidelines recommend the use of pacritinib as a potential treatment option in patients with myelofibrosis associated anemia

Gamifant: US FDA approves MAS in Still's disease

Strong sales growth driven by an increase in the number of patients on treatment and positive patient mix

Gamifant
SEK 632 M
+33% Q2



FDA approves, after priority review Gamifant as first-ever treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still's disease

- Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies showing at week 8:
  - 54% of patients had a complete response
  - 82% achieved clinical MAS remission (VAS ≤1 cm)

Sales in SEK M at actual exchange rates; change at constant exchange rates.

Q2 2025 Revenue and profit & loss



Absolute amounts in SEK million (except EPS) and at actual exchange rates; change at actual exchange rates (statutory view).

Amounts in SEK M	Q2 2025	Q2 2024	Change	Full-year 2024
Total revenue	**6,175**	5,442	13%	**26,027**
Adjusted Gross profit [1,2]	**4,781**	4,166	15%	**20,326**
Adjusted Gross margin [1,2]	**77%**	77%		**78%**
EBITA [1]	**1,863**	1,486	25%	**9,158**
Adjusted EBITA [1,2]	**2,100**	1,515	39%	**9,368**
EBITA margin [1]	**30%**	27%		**35%**
Adjusted EBITA margin [1,2]	**34%**	28%		**36%**
Profit for the period	**634**	224	183%	**3,879**
EPS, before dilution, SEK	**1.85**	0.66	181%	**11.37**
Adjusted EPS, before dilution, SEK [1,2]	**2.38**	0.72	>200%	**11.83**
Operating cash flow	**1,448**	2,329	-38%	**7,388**
Net debt [1]	**11,386**	16,028		**15,194**

1. Alternative Performance Measures (APM); see the report for further information
2. Items affecting comparability (IAC); see the report for further information

Sobi Outlook 2025

Key considerations for 2025

- Altuvoct launch progress
- Continued progress with commercial portfolio
- Beyfortus royalty
- Launch preparation
  - In US for NASP in uncontrolled gout
  - In Europe for Aspaveli in nephrology
- New studies – e.g. Altuvoct, Vonjo VEXAS and CMML
- Ongoing major registrational activities – Aspaveli, Gamifant and NASP

2025 outlook

Revenue

Anticipated to grow by a high single-digit percentage at CER

Adjusted EBITA margin

Anticipated to be in the mid-30s percentage of revenue

NASP: nanoencapsulated sirolimus plus pegadricase, CMML: Chronic Myelomonocytic Leukemia

Sustainability at Sobi

Sustainability strategy drives business priorities

Commitment to patients

- Access to treatment
- Patient centricity and engagement
- Patient and product safety
- Responsible marketing & sales
- Ethical R&D, focused on medical need

Responsible behaviour

- Safe, fair, and healthy work
- Inclusive, diverse workplace
- Lower environmental footprint
- Less resource consumption
- Compliance and anti-corruption

The priorities are based on 21 key sustainability topics, covering climate, pollution, water, circularity, people, and business ethics.

Sobi's climate targets approved by SBTi

SCIENCE BASED TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

In 2024, Sobi qualified for the third time as a constituent of the **Dow Jones Best-in-Class Europe Index (EUR)**.

Commitment to patients

For more details:
Sustainability performance | Sobi

Access to treatment

~ 42,000 people treated* with medicines from Sobi.



9
projects from Phase 2 through registration

7
medicines or potential new medicines in development

Humanitarian aid

Continued support for WFHs* Humanitarian Aid Program.

>22,000
people reported treated since programme start

>1,300
surgeries in 2024

>17,000
acute bleeds treated in 2024

885 M
International units of factor donated since programme start

Patient centricity

- **Four** international patient councils to advise on early clinical development.
- **525** employees completed training in patient centric practices through an initiative by Patient Focused Medicine Development (PFMD).

- Long-term sponsorships of **EURORDIS**, **NORD**, **WFH**, **EHC** and local patient organisations.*

* Measured as full-time equivalent patients, excluding use in pandemic related conditions

* World Federation of Hemophilia, International Units

* European Organisation for Rare Diseases, National Organization for Rare Disorders, European Haemophilia Consortium

Always act responsibly

For more details:
Sustainability performance | Sobi

Caring for employees

Gender composition (%)

	♀	♂
Senior management	39	61
Overall	60	40

- Launch of **DEI** training toolbox & employee awareness month

>26,000
hours of locally managed training on leadership and personal development registered

Reduced footprint

- A **77%** reduction in CO_2-intensity between 2016 and 2023 (from **0,3** to **0,07 tonnes CO_2/MSEK**)



- Transformation of car fleet



Responsible sourcing

95%
of Sobi's CMOs* scored by EcoVadis

Mean score **64**
between "good" and "advanced"

- Supplier climate targets



- Sobi supplier practices

* Contract manufacturers
** Science Based Targets

Compliance

95%
completed Code of Conduct training

91%
completed newly released ABAC-training*

91%
completed training on data privacy and information security

* Anti-bribery, anti-corruption

Pipeline and upcoming news flow

Solid pipeline progress in Q2 2025

Aspaveli/ Empaveli	**C3G and IC-MPGN** VALIANT 52-week: consistent efficacy & safety
	TA-TMA Discontinued after Phase 2 strategic review
Gamifant	**HLH/MAS in Still's disease** FDA approved extended indication
NASP	**Uncontrolled gout** FDA rolling submission completed
Vonjo	**VEXAS** First patient enrolled in PAXIS study
Altuvoct	**Joint health** First patient enrolled in ALTITUDE Phase 4 study

C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. **TA-TMA:** Transplant-associated Thrombotic Microangiopathy. **HLH/MAS:** Haemophagocytic lymphohistiocytosis / macrophage activation syndrome. **NASP:** Nanoencapsulated sirolimus plus pegadricase (formerly known as SEL-212). **VEXAS:** Vacuoles E1 Ub activating enzyme X-linked Auto-inflammatory disease with Somatic mutations.

Progress to be continued in 2025-26

Anticipated pipeline news flow

2025 H2

Aspaveli – C3G & IC-MPGN
- EU CHMP opinion
- Japan regulatory submission

Gamifant – HLH / MAS in Still's disease
- Japan regulatory submission

Gamifant – IDS
- Phase 2a data (proof of concept research collaboration)

Kineret – Still's disease
- Japan regulatory submission

Doptelet – ITP
- US: Paediatrics regulatory decision
- Japan regulatory decision

Olezarsen – FCS
- EU regulatory decision

2026

Aspaveli – C3G & IC-MPGN
- EU regulatory decision
- Japan regulatory decision

Gamifant – HLH / MAS in Still's disease
- Japan regulatory decision

NASP – Uncontrolled gout
- US regulatory decision

Zynlonta – DLBCL 2L
- LOTIS-5 data readout

Altuvoct – Haemophilia A
- FREEDOM Phase 3b initial study data

C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. **HLH/MAS:** Haemophagocytic lymphohistiocytosis / macrophage activation syndrome. **IDS:** Interferon gamma driven sepsis. **FCS:** Familial chylomicronemia syndrome. **NASP:** Nanoencapsulated sirolimus plus pegadricase (formerly known as SEL-212). **DLBCL:** Diffuse large B-cell lymphoma.

Sobi IR contacts



[Investors page on sobi.com]

Gerard Tobin

Head of Investor Relations

gerard.tobin@sobi.com

+41 79 286 28 83

Jen Kretzmann

Manager of Stakeholder Communication and Corporate Access

jennifer.kretzmann@sobi.com

+44 7423 031 070

Michael Greksa

Investor Relations North America

michael.greksa@sobi.com

+1 (704) 420-0473

Notes on Haemophilia and RSV business

Haemophilia

- Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US.
- Sobi has final development and commercialisation rights in the **Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets).**
- Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.

Link to press release

RSV

- Synagis – Sobi has commercialisation rights in the US
- Beyfortus – Marketed and sold by Sanofi in the US and ROW
    - Sobi receives royalties on US sales
    - Royalty rates started at 25% at launch, continue in 2024 and increase each year from 2025 to 2028 in a tiered fashion to a range of 30-35% of net sales. Beyond 2028, the royalty rates will remain at these levels.

Link to press release

Sobi.com / media / press releases

Thank you

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm • Sweden
www.sobi.com